IL17A and psoriasis: Studies in IL-23- or imiquimod (IMQ; a Toll-like receptor 7/8 agonist)-induced mouse models of psoriasis show that psoriatic inflammation is impaired in IL-22- and IL-17-deficient mice, thereby confirming the role of the IL-23/IL-17 axis4,5.